Arrowhead Pharmaceuticals Inc (ARWR) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Total Assets Chart for Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc (ARWR) total assets for FY2025 were USD 1.4B, a 21.5% change from FY2024. Arrowhead Pharmaceuticals Inc's total assets grew from USD 107.7K in 1997 to USD 1.4B in 2025 (1286404.3% over 28 years). Total assets compound annual growth rate: 5-year CAGR of 21.5%, 10-year CAGR of 26.5%, 20-year CAGR of 21.3%.
Total Assets (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $8.67B
- Implied Share Price
- $61.54
- Enterprise Value
- $8.84B
- Revenue (TTM)
- $669.49M
- EBITDA
- -$200.64M
- Profit Margin
- -47.79%
- Trailing P/E
- —
- Forward P/E
- 111.11
- Price/Book (MRQ)
- 20.55
- Price/Sales (TTM)
- 12.98
- EV/EBITDA
- 27.85
- EV/Revenue
- 13.37
- Dividend Yield
- —
- Book Value
- $3.30
- Free Cash Flow (FY2025)
- $156.89M
- Free Cash Flow Yield
- 1.81%
Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.